CompRest - a Comparison Between Sleep Compression and Sleep Restriction for Treating Insomnia
Launched by KAROLINSKA INSTITUTET · Apr 14, 2016
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical level of Insomnia (more than 10 on ISI)
- • Meets criteria for Insomnia Disorder according to DSM-V
- • Sufficient language skills
- • Having access to Internet to fill out forms and participating in treatment
- • Not foresee obstacles to participating in treatment during the coming 20 weeks, or participating in measurements during the coming year.
- Exclusion Criteria:
- • Sleep disorders requiring other treatment
- • High consumption of alcohol/drugs that affect sleep
- • Somatic or psychiatric conditions counter-indicative of treatments given in the study, requiring acute care, or with symptoms and level of functioning affecting the ability to participate in the treatment programs.
- • Working (night) shifts
- • Ongoing psychological treatment for Insomnia with sleep restriction or sleep compression as a treatment component - also previous such treatment can be excluding
- • Use of sleep medication in such a way that may hinder the implementation of the methods in this treatment
- • Pre-treatment measurements not finished within the given time-frame.
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Trial Officials
Susanna Jernelöv, PhD
Principal Investigator
Karolinska Institutet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials